Antithrombotic Drugs Market by Drug Type – Platelet Aggregation Inhibitors (PAIs); Fibrinolytics; Anticoagulants – Low-Molecular-Weight Heparins (LMWHs), Vitamin K Antagonists (VKAs), Direct Thrombin Inhibitors (DTIs), Direct Factor Xa Inhibitors (FXa); Other Antithrombotic Agents and Forecast 2017-2021

Antithrombotic Drugs Market by Drug Type – Platelet Aggregation Inhibitors (PAIs); Fibrinolytics; Anticoagulants – Low-Molecular-Weight Heparins (LMWHs), Vitamin K Antagonists (VKAs), Direct Thrombin Inhibitors (DTIs), Direct Factor Xa Inhibitors (FXa); Other Antithrombotic Agents and Forecast 2017-2021

Antithrombotic drugs in routine use include antiplatelet drugs (aspirin, clopidogrel, and glycoprotein IIb/IIIa receptor antagonists) and anticoagulants (unfractionated and low molecular weight heparin, warfarin, and direct thrombin inhibitors). The use of antithrombotic therapy in acute coronary syndromes has reduced the incidence of death and Q wave myocardial infarction dramatically in recent years. Antithrombotic drugs are categorized into three broad types: platelet aggregation inhibitors (PAIs), fibrinolytics and anticoagulants. PAIs prevent blood clots by blocking one of the platelet surface receptors and are mainly used for long-term management of arterial thrombosis. Fibrinolytics allow reperfusion by converting plasminogen to plasmin and dissolving fibrin. Anticoagulants, used as short- and long-term options for both arterial and venous thrombi, comprise low-molecular-weight heparins (LMWHs), vitamin K antagonists (VKAs), direct thrombin inhibitors (DTIs) and direct factor Xa (FXa) inhibitors. Several promising therapies, particularly targeting the warfarin replacement are in the development pipeline. Antithrombotic therapy has had an enormous impact in several significant ways. Heparin has made bypass surgery and dialysis possible by blocking clotting in external tubing. Antithrombotic therapy has reduced the risk of blood clots in leg veins (also known as deep-vein thrombosis or DVT), a condition that can lead to death from pulmonary embolism by more than 70 percent. And most importantly, it has markedly reduced death from heart attacks, the risk of stroke in people with heart irregularities (atrial fibrillation), and the risk of major stroke in patients with mini-strokes.

The global antithrombotic drugs market segmentation is based on drug type – platelet aggregation inhibitors (PAIs); fibrinolytics; anticoagulants – low-molecular-weight heparins (LMWHs), vitamin K antagonists (VKAs), direct thrombin inhibitors (DTIs), direct factor Xa inhibitors (FXa); and other antithrombotic agents.

The global antithrombotic drugs market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global antithrombotic drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global antithrombotic drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global antithrombotic drugs market and profiled in this report include Armetheon, Armetheon, Bayer, Boehringer Ingelheim, Bristol-Myers Squib, Daiichi Sankyo, D‑Pharm, Endotis Pharma, Janssen, Lundbeck, Merck & Co., Pfizer, Portola Pharmaceuticals, Regado Biosciences, Roche, TeaRx, and The Medicines Company.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Antithrombotic Drugs Market

1. Drug Type
1.1. Platelet Aggregation Inhibitors (PAIs)
1.2. Fibrinolytics
1.3. Anticoagulants
1.3.1. Low-Molecular-Weight Heparins (LMWHs)
1.3.2. Vitamin K Antagonists (VKAs)
1.3.3. Direct Thrombin Inhibitors (DTIs)
1.3.4. Direct Factor Xa Inhibitors (FXa)
1.4. Other Antithrombotic Agents

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World

3. Company Profiles
3.1. Armetheon
3.2. Armetheon
3.3. Bayer
3.4. Boehringer Ingelheim
3.5. Bristol-Myers Squib
3.6. Daiichi Sankyo
3.7. D‑Pharm
3.8. Endotis Pharma
3.9. Janssen
3.10. Lundbeck
3.11. Merck & Co.
3.12. Pfizer
3.13. Portola Pharmaceuticals
3.14. Regado Biosciences
3.15. Roche
3.16. TeaRx
3.17. The Medicines Company

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*